Researchers at Moffitt Cancer Center report encouraging early results from a phase 2 study examining whether immunotherapy can improve results when added to radiotherapy-based treatment regimen for men with aggressive prostate cancer. The work, led by Kosj Yamoah, MD, Ph.D., chair of the Radiation Oncology Department at Moffitt, was published in the Journal for ImmunoTherapy of Cancer.